专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020257135A1 TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2020257135A1
公开(公告)日：2020-12-24
申请号：PCT/US2020/037836
申请日：2020-06-16
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： CHENG, Peter Tai Wah , ZHANG, Hao , KALTENBACH, III, Robert F. , LI, Jun , SHI, Jun , TAO, Shiwei , SHI, Yan
IPC分类号： A61P1/16 , A61P13/12 , A61P19/10 , A61P29/00 , A61P35/00 , A61P37/06 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/4439 , A61K31/506
摘要： The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

2. 发明申请

WO2019126098A1 PYRAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2019126098A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066127
申请日：2018-12-18
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： CHENG, Peter Tai Wah , LI, Jun , SHI, Yan , WANG, Ying , ZHANG, Hao , KENNEDY, Lawrence J. , WALKER, Steven J. , REDDIGUNTA, Ramesh Babu
IPC分类号： C07D231/12 , C07D401/04 , C07D403/04 , A61K31/415 , A61K31/4427 , A61K31/496 , A61P43/00
CPC分类号： C07D401/04 , C07D231/12 , C07D403/04
摘要： The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

3. 发明申请

WO2009018065A3 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME 审中-公开
公开(公告)号：WO2009018065A3
公开(公告)日：2009-02-05
申请号：PCT/US2008/070962
申请日：2008-07-24
申请人： BRISTOL-MYERS SQUIBB COMPANY , SHI, Yan , CHENG, Peter, T., W. , WANG, Ying , RYONO, Denis, E.
发明人： SHI, Yan , CHENG, Peter, T., W. , WANG, Ying , RYONO, Denis, E.
IPC分类号： C07D213/81 , C07D231/14 , C07D233/90 , C07D241/24 , C07D249/10 , C07D277/56 , C07D277/68 , C07D471/04 , C07D513/04 , C07C237/22 , A61K31/426 , A61K31/4196 , A61K31/4164 , A61P3/00
摘要： Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure Formula: (I); where Q is Formula: (II); or Formula: (III); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

4. 发明申请

WO2008005964A2 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME 审中-公开
标题翻译：新型GLUCOKINASE激活剂及其使用方法
公开(公告)号：WO2008005964A2
公开(公告)日：2008-01-10
申请号：PCT/US2007/072708
申请日：2007-07-03
申请人： BRISTOL-MYERS SQUIBB COMPANY , RYONO, Dennis E. , CHENG, Peter T.W. , BOLTON, Scott A. , CHEN, Sean S. , SHI, Yan , MENG, Wei , TINO, Joseph A. , ZHANG, Hao , SULSKY, Richard B.
发明人： RYONO, Dennis E. , CHENG, Peter T.W. , BOLTON, Scott A. , CHEN, Sean S. , SHI, Yan , MENG, Wei , TINO, Joseph A. , ZHANG, Hao , SULSKY, Richard B.
IPC分类号： C07F9/32 , C07F9/40 , A61K31/675 , A61P3/00
CPC分类号： C07F9/6539 , C07F9/582 , C07F9/587 , C07F9/65032 , C07F9/650964 , C07F9/650982 , C07F9/65181
摘要： Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure of Formula (I), wherein Formula (II) is a heteroaryl ring; R 4 is -(CH 2 ) n -Z-(CH 2 ) m -PO(OR 7 )(OR 8 ), -(CH 2 ) n Z-(CH 2 ) m -PO(OR 7 )R 9 , -(CH 2 ) n -Z-(CH 2 ) m -OPO(OR 7 )R 9 , -(CH 2 ) n Z-(CH 2 ) m -OPO(R 9 )(R 10 ), or -(CH 2 ) n Z-(CH 2 ) m -PO(R 9 )(R 10 ); R 5 and R6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
摘要翻译：提供了膦酸酯和次膦酸酯活化剂的化合物，因此可用于治疗糖尿病和相关疾病，并具有式（I）的结构，其中式（II）是杂芳基环; R 4是 - （CH 2 CH 2）n - （CH 2）n - （OR 7）（OR 8）， - （CH 2 CH 2）n - Z - （ CH 2 OR 2（OR 7）R 9， - （CH 2 CH 2） SUB>）_{名词 -Z-（CH _{2 ）_{米 -OPO（OR _{7 ）R _{9 - （CH 2）n - Z - （CH 2）2 - （O） - （CH 2）n - （R 10），或 - （CH 2）n - Z - （CH 2） 2 ）_{米 -PO（R _{9 ）（R _{10 ）; R 5和R 6独立地选自H，烷基和卤素; Y是R 7（CH 2）2，或不存在; 和X，n，Z，m，R 4，R 5，R 6，R 7，和 s如本文所定义; 或其药学上可接受的盐。还提供了使用上述化合物治疗糖尿病和相关疾病的方法。}}}}}}}}

5. 发明申请

WO2019126094A1 CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2019126094A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066123
申请日：2018-12-18
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SHI, Yan , CHENG, Peter Tai Wah , WANG, Ying , LI, Jun , FANG, Tianan , CORTE, James R. , SHI, Jun , ZHANG, Hao , KENNEDY, Lawrence J. , TAO, Shiwei
IPC分类号： C07D401/14 , C07D413/14 , C07D417/14 , A61K31/4192 , A61P35/00
摘要： The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

6. 发明申请

WO2019126085A1 PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2019126085A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066110
申请日：2018-12-18
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SHI, Yan , CHENG, Peter Tai Wah , WANG, Ying
IPC分类号： C07D401/04 , A61K31/4439 , A61K31/506 , C07D403/04 , A61P35/00 , A61P11/06
CPC分类号： C07D401/04 , A61P11/06 , A61P35/00 , C07D403/04
摘要： The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 , and X 4 are each independently CR 6 or N; provided that no more than two of X 1 , X 2 , X 3 , or X 4 are N; Q 2 is N or NR 5a ; one of Q 1 and Q 3 is CR 5 , and the other is N or NR 5a ; and the dashed circle denotes optional bonds forming an aromatic ring; Y 1 is O or NR 3 ; Y 2 is -CO-, -SO 2 -, or -S(O(NH)-; Y 3 is O or NR 4a ; provided that (1) Y 1 and Y 3 are not both O, and (2) when Y 2 is C(O), Y 1 is not O; L is a covalent bond or C 1-4 alkylene substituted with 0 to 4 R 7 ; R 1 is (-CH 2 ) a R 9 ; a is an integer of 0 or 1; R 2 is each independently halo, cyano, hydroxyl, amino, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R 3 and R 4a are independently hydrogen, C 1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 4 is C 1-10 alkyl, C 1-10 haloalkyi, C 1-10 deuterated alkyl, C 1-10 alkenyl, C 3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, -(Ci-6 alkylene)-(C3-8 cycloalkyl), -(C 1-6 alkylene)-(6 to 10-membered aryl), -(C 1-6 alkylene)-(3 to 8-membered heterocyclyl), or -(C 1-6 alkylene)-(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, R 3 and R 4 , taken together with the N and 0 atoms which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R 8 ; or alternatively, (R 3 and R 5a ) or (R 3 and R 5 ), taken together with the atoms to which they are attached to, form a 5 to 8-membered heterocyclic ring moiety which is substituted with 0 to 3 R 8 ; R 5a is hydrogen, C 1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 5 and R 6 are each independently hydrogen, halo, cyano, hydroxyl, amino, alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 7 is halo, oxo, cyano, hydroxyl, amino, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 8 are each independently deuterium, halo, hydroxyl, amino, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R 8 , taken together with the atom(s) to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R 12 ; R 9 is selected from -CN, -C(O)OR 10 , -C(O)NR 11a R 11b , -CO-NH-CO-R e , -CO-NH-SO 2 -R e , -CO-NH-SO-R e ,-SO 2 -OH, -SO 2 -NH-CO-R e , -P(O)(OH) 2 , tetrazol-5-yl, -CH 2 -CO-NH-CO-R e , -CH 2 -CO-NH-SO 2 -R e , -CH 2 -CO-NH-SO-R e , -CH 2 -SO 2 -OH, -CH 2 -SO 2 -NH-CO-R e , -CH 2 -P(O)(OH) 2 , tetrazol-5-ylmethylene; R e is C 1-6 alkyl, C 3-6 cycloalkyl, haloalkyl, hydroxyalkyi, aminoalkyi, alkoxyalkyi, or haloalkoxyalkyi; R 10 is hydrogen or C 1-10 alkyl; and R 11a and R 11b are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, or haloalkoxy; and R 12 is halo, cyano, hydroxyl, amino, C 1-6 alkyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors.

7. 发明申请

WO2016040223A1 CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS 审中-公开
标题翻译：含有羧基酸GPR120调节剂的CYCLOBUTANE
公开(公告)号：WO2016040223A1
公开(公告)日：2016-03-17
申请号：PCT/US2015/048782
申请日：2015-09-08
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SHI, Yan , WANG, Ying , CHENG, Peter T.W. , WU, Shung C.
IPC分类号： C07C59/72 , C07D213/643 , C07D213/70 , C07C59/90 , C07C62/34 , A61K31/192 , A61P9/10 , A61P3/06 , A61P3/10
CPC分类号： C07C59/72 , A61K31/192 , A61K31/343 , A61K31/351 , A61K31/4245 , A61K31/426 , A61K31/4418 , A61K31/50 , A61K45/06 , C07C59/90 , C07C62/34 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/50 , C07C2603/50 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/14 , C07D271/06 , C07D277/24 , C07D307/79 , C07D309/12
摘要： The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
摘要翻译：本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。

8. 发明申请

WO2002042273A3 ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS 审中-公开
公开(公告)号：WO2002042273A3
公开(公告)日：2002-05-30
申请号：PCT/US2001/046884
申请日：2001-11-07
申请人： BRISTOL-MYERS SQUIBB COMPANY , BISACCHI, Gregory, S. , SUTTON, James, C., Jr. , SLUSARCHYK, William, A. , TREUNER, Uwe, D. , ZHAO, Guohua , CHENEY, Daniel, L. , WU, Shung, C. , SHI, Yan
发明人： BISACCHI, Gregory, S. , SUTTON, James, C., Jr. , SLUSARCHYK, William, A. , TREUNER, Uwe, D. , ZHAO, Guohua , CHENEY, Daniel, L. , WU, Shung, C. , SHI, Yan
IPC分类号： C07D401/12
摘要： Compounds having the formula (I), are useful as serine protease inhibitors, more particularly inhibitors of Factors VIIa, Ixa, Xa, and/or Xia, wherein ring B is phenyl or pyridyl, W is preferably C(=O)NR 4 R 5 , L is a linker group, X 2 comprises nitrogen or carbon, Z is an optionally-substituted monocyclic or bicyclic ring system, and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification.

9. 发明申请

WO2019126103A1 CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2019126103A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066136
申请日：2018-12-18
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SHI, Yan , CHENG, Peter Tai Wah , ZHANG, Hao , LI, Jun , FANG, Tianan , CORTE, James R.
IPC分类号： A61P35/00 , A61P11/06 , C07D413/14 , A61K31/4155 , A61K31/4192 , A61K31/4245 , A61K31/433 , A61K31/506 , C07D403/14 , C07D417/14
CPC分类号： A61P11/06 , A61P35/00 , C07D403/14 , C07D413/14 , C07D417/14
摘要： The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

10. 发明申请

WO2019126099A1 ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS 审中-公开
公开(公告)号：WO2019126099A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066128
申请日：2018-12-18
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： CHENG, Peter Tai Wah , SHI, Yan , KALTENBACH, Robert F. III , WANG, Ying , ZHANG, Hao
IPC分类号： C07D261/08 , A61P35/00 , A61K31/415
CPC分类号： C07D261/08 , A61P35/00
摘要： The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式